You Ma		- S ensin receptor-neprilysin ir n myocardial infarction aft	nhibitor (Sacubitril/Valsartan) versus Enalapril in patients er primary PCI: a prospective randomized trial 6	with
rel par to	ated to the content of your rities whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ons any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply inuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperte dication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other item	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		

Time frame: past 36 months

_X__None

X__None

X__None

2

3

4

Grants or contracts from any entity (if not indicated

in item #1 above).
Royalties or licenses

Consulting fees

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nava	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the	following box:
	and reminiatize the above of	oor or interest in the	
	None.		
L			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

D	
Date:Aug. 27 th , 2021	
Your Name:Yan Xu	
Manuscript Title: Angiotensin recept	or-neprilysin inhibitor (Sacubitril/Valsartan) versus Enalapril in patients with
acute anterior wall ST-elevation myocardia	Il infarction after primary PCI: a prospective randomized trial
Manuscript number (if known):	CDT-21-386
related to the content of your manuscript. parties whose interests may be affected by	to disclose all relationships/activities/interests listed below that are "Related" means any relation with for-profit or not-for-profit third the content of the manuscript. Disclosure represents a commitment adicate a bias. If you are in doubt about whether to list a ble that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nava	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the	following box:
	and reminiatize the above of	oor or interest in the	
	None.		
L			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

Yo Ma acı		- B ensin receptor-neprilysin in n myocardial infarction aft	nhibitor (Sacubitril/Valsartan) versus Enalapril in patient er primary PCI: a prospective randomized trial 66	s with
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hypertodication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other iter	9
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

No time limit for this item.

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nava	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the	following box:
	and reminiatize the above of	oor or interest in the	
	None.		
L			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

Da	Aug. 27 th , 2021					
Yo	Name: Zuozhong Yu					
	lanuscript Title: Angiotensin receptor-neprilysin inhibitor (Sacubitril/Valsartan) versus Enalapril in patients with cute anterior wall ST-elevation myocardial infarction after primary PCI: a prospective randomized trial					
Ma	uscript number (if known):CDT-21-386					
rel par to	e interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are ed to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third es whose interests may be affected by the content of the manuscript. Disclosure represents a commitment insparency and does not necessarily indicate a bias. If you are in doubt about whether to list a onship/activity/interest, it is preferable that you do so.					
	ollowing questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>iscript only</u> .					
to	uthor's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains e epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive cation, even if that medication is not mentioned in the manuscript.					
	m #1 below, report all support for the work reported in this manuscript without time limit. For all other items, me frame for disclosure is the past 36 months.					
	Name all entities with Specifications/Comments					
	whom you have this (e.g., if payments were made to you or to your					

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame. Since the linual	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	V. Nava	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the	following box:
	and reminiatize the above of	oor or interest in the	
	None.		
L			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

Da	te: Aug. 27 th , 2021					
	ur Name: Zhide Yu	_				
		ensin receptor-neprilysin	inhibitor (Sacubitril/Valsartan) versus Enalapril in pati	ents with		
	cute anterior wall ST-elevation myocardial infarction after primary PCI: a prospective randomized trial					
	anuscript number (if known)	-				
In	the interest of transparency	, we ask you to disclose al	I relationships/activities/interests listed below that a	re		
re	ated to the content of your	manuscript. "Related" me	ans any relation with for-profit or not-for-profit third			
pa	rties whose interests may be	e affected by the content	of the manuscript. Disclosure represents a commitme	nt		
		-	. If you are in doubt about whether to list a			
re	ationship/activity/interest,	it is preferable that you d	o so.			
	e following questions apply	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>			
11119	anascript only.					
	•	-	defined broadly. For example, if your manuscript per a all relationships with manufacturers of antihypertens			
	edication, even if that medic	· -	-	5140		
	careation, even in that means	action is not inclinioned in	the manuscripti			
In	item #1 below, report all sur	pport for the work reporte	ed in this manuscript without time limit. For all other	items.		
	e time frame for disclosure i	-	•	,		
		•				
		Name all entities with	Specifications/Comments	1		
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as	,			
		needed)				
		Time frame: Since the initia	ll planning of the work			
	All support for the present	XNone				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.) No time limit for this item.					
	NO time illuit for this item.					
	I	1		1		

Time frame: past 36 months

X__None

X__None

_X__None

Grants or contracts from

in item #1 above).
Royalties or licenses

Consulting fees

any entity (if not indicated

2

3

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	·		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	anoidi interesto		
Ple	ease summarize the above o	onflict of interest in the	following box:
	None.		
_			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

You Ma		- ensin receptor-neprilysin i n myocardial infarction af	nhibitor (Sacubitril/Valsartan) versus Enalapril in patie ter primary PCI: a prospective randomized trial 36	ents with
rel par to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmen If you are in doubt about whether to list a o so.	
The to me	e author's relationships/acti the epidemiology of hyperte edication, even if that medic	ivities/interests should be ension, you should declare ation is not mentioned in pport for the work reporte	ps/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pert all relationships with manufacturers of antihypertens the manuscript. d in this manuscript without time limit. For all other in	sive
		•		
		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			r planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone		

		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

No time limit for this item.

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	·		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	diloidi iireereoto		
Ple	ease summarize the above o	onflict of interest in the	following box:
	None.		
_			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

You Ma		- ensin receptor-neprilysin in n myocardial infarction aft	nhibitor (Sacubitril/Valsartan) versus Enalapril in patie er primary PCI: a prospective randomized trial 66	nts with
rel par to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitmen If you are in doubt about whether to list a so.	
	e following questions apply inuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to me	the epidemiology of hyperte dication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reporte	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertens the manuscript. d in this manuscript without time limit. For all other it	ive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
l	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone		

	No time limit for this item.	
		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	X_None
4	Consulting fees	XNone

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
	·		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
	anoidi interesto		
Ple	ease summarize the above o	onflict of interest in the	following box:
	None.		
_			
Ple	ease place an "X" next to the	following statement to	indicate your agreement:

Da	te:Aug. 27 th , 2021			
	ur Name:Xinghua Jiang_	_		
			hibitor (Sacubitril/Valsartan) versus Enalapril in patier	ts with
			er primary PCI: a prospective randomized trial	
	anuscript number (if known)	=		
		,,		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" mea e affected by the content of necessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment lf you are in doubt about whether to list a so.	
	e following questions apply anuscript only.	to the author's relationship	s/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare a	lefined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensione manuscript.	
	item #1 below, report all su e time frame for disclosure i	•	in this manuscript without time limit. For all other ite	ems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initial	planning of the work	
	All support for the present			
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past 3	26 months	
)	Grants or contracts from	X None	o months	
_	any entity (if not indicated	^_None		
	in item #1 above).			
}	Royalties or licenses	X None		
•	Noyunces of ficenses	X_NONC		
ļ	Consulting fees	X None		
	_	l — —	+	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone			
6	Payment for expert testimony	XNone			
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or pending	XNone			
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone			
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone			
11	Stock or stock options	XNone			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None			
13	Other financial or non- financial interests	XNone			
Ple	Please summarize the above conflict of interest in the following box:				

None.			

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.